Page Title
Drug Development Pipeline
Vanzacaftor + tezacaftor + deutivacaftor
Status
Phase ThreeTherapeutic Approach
Restore CFTR Protein
This program is studying a combination therapy combining three CFTR modulators. Vanzacaftor (VX-121) and tezacaftor are CFTR correctors, a type of modulator designed to fix the defective CFTR protein so that it can move to the proper place on the cell surface. Deutivacaftor (VX-561) is an altered form of the potentiator ivacaftor (Kalydeco®). Potentiators are drugs that facilitate the opening of the chloride channel on the cell surface to allow chloride and sodium (salt) to move in and out of the cell. Deutivacaftor may be more stable in the body than regular ivacaftor, which would allow it to be taken once a day.
Status
A phase 2 study to test the safety and effectiveness of vanzacaftor + tezacaftor + deutivacaftor in adults with CF was completed.
A phase 3 study is currently underway to test this triple combination therapy in people with CF who are 12 years and older. The study is for people with one copy of the F508del mutation and one copy of a minimal function mutation.
Sponsor
This program is sponsored by Vertex Pharmaceuticals. This program is being conducted within the Therapeutics Development Network (TDN).
Recent Vanzacaftor + tezacaftor + deutivacaftor Studies
-
Closed to Enrollment
Study of VX-121 in people with CF ages 12 years and older who have either two copies of the F508del mutation, one copy of the F508del mutation and one copy of a gating or residual function mutation, or no copies of the F508del mutation and at least one other triple combination responsive CFTR mutation (Vertex VX20-121-103)
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More